In tumor cells, for instance, gemcitabine-metabolizing enzyme levels and activity such as CDA, dCK or Nt5c1A/Nt5c3 may explain the discrepancy between high hENT1 level and poor response to gemcitabine [3,16]. This evidence concerns the gene CDA and neoplasm.